These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21119723)

  • 1. Trial watch: targeting IL-17A shows broad promise in autoimmune diseases.
    Nat Rev Drug Discov; 2010 Dec; 9(12):908. PubMed ID: 21119723
    [No Abstract]   [Full Text] [Related]  

  • 2. The IL-17 pathway as a major therapeutic target in autoimmune diseases.
    Hu Y; Shen F; Crellin NK; Ouyang W
    Ann N Y Acad Sci; 2011 Jan; 1217():60-76. PubMed ID: 21155836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-17 as a drug target in human disease.
    Ivanov S; Lindén A
    Trends Pharmacol Sci; 2009 Feb; 30(2):95-103. PubMed ID: 19162337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-17A: A Potential Therapeutic Target in Chronic Lung Diseases.
    Shaikh SB; Prabhu A; Bhandary YP
    Endocr Metab Immune Disord Drug Targets; 2019; 19(7):921-928. PubMed ID: 30652654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases.
    Skundric DS
    Cent Nerv Syst Agents Med Chem; 2018 Jan; 18(1):3. PubMed ID: 29474167
    [No Abstract]   [Full Text] [Related]  

  • 6. Genomics drugs in clinical trials.
    Hall J; Dennler P; Haller S; Pratsinis A; Säuberli K; Towbin H; Walther K; Woytschak J
    Nat Rev Drug Discov; 2010 Dec; 9(12):988. PubMed ID: 21119735
    [No Abstract]   [Full Text] [Related]  

  • 7. A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases.
    Lyman M; Lieuw V; Richardson R; Timmer A; Stewart C; Granger S; Woods R; Silacci M; Grabulovski D; Newman R
    J Biol Chem; 2018 Jun; 293(24):9326-9334. PubMed ID: 29678878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting IL-17 and IL-23 in Immune Mediated Renal Disease.
    Ghali JR; Holdsworth SR; Kitching AR
    Curr Med Chem; 2015; 22(38):4341-65. PubMed ID: 26521930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation.
    Santibanez JF; Bjelica S
    Recent Pat Anticancer Drug Discov; 2018; 13(2):133-144. PubMed ID: 29468982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-33: a potential therapeutic target in autoimmune diseases.
    Wang S; Ding L; Liu SS; Wang C; Leng RX; Chen GM; Fan YG; Pan HF; Ye DQ
    J Investig Med; 2012 Dec; 60(8):1151-6. PubMed ID: 23076162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the IL-17-T(H)17 pathway.
    Bartlett HS; Million RP
    Nat Rev Drug Discov; 2015 Jan; 14(1):11-2. PubMed ID: 25549584
    [No Abstract]   [Full Text] [Related]  

  • 12. The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders.
    Roeleveld DM; van Nieuwenhuijze AE; van den Berg WB; Koenders MI
    BioDrugs; 2013 Oct; 27(5):439-52. PubMed ID: 23620106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application.
    Ariza ME; Williams MV; Wong HK
    Clin Immunol; 2013 Feb; 146(2):131-9. PubMed ID: 23314273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial watch: phase II boost for glutamate-targeted antidepressants.
    Flight MH
    Nat Rev Drug Discov; 2013 Dec; 12(12):897. PubMed ID: 24287771
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting Th17 Effector Cytokines for the Treatment of Autoimmune Diseases.
    Yamagata T; Skepner J; Yang J
    Arch Immunol Ther Exp (Warsz); 2015 Dec; 63(6):405-14. PubMed ID: 26358867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diseases that may benefit from manipulating the Th17 pathway.
    Miossec P
    Eur J Immunol; 2009 Mar; 39(3):667-9. PubMed ID: 19283719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological modulation of Th17.
    De Sanctis JB; Garmendia JV; Moreno D; Larocca N; Mijares M; Di Giulio C; Salazar-Bookaman M; Wojewodka G; Radzioch D
    Recent Pat Inflamm Allergy Drug Discov; 2009 Jun; 3(2):149-56. PubMed ID: 19519592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapeutic targets along the Th17 pathway.
    Ouyang W; Filvaroff E; Hu Y; Grogan J
    Eur J Immunol; 2009 Mar; 39(3):670-5. PubMed ID: 19283720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of IL-17A blockade with secukinumab in autoimmune diseases.
    Patel DD; Lee DM; Kolbinger F; Antoni C
    Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii116-23. PubMed ID: 23253932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the role of Interleukin 17 in rheumatologic autoimmune diseases.
    Konya C; Paz Z; Apostolidis SA; Tsokos GC
    Cytokine; 2015 Oct; 75(2):207-15. PubMed ID: 26028353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.